News|Articles|March 2, 2026

FDA updates in urology: February 2026

Author(s)Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2026.

Welcome to Urology Times’® monthly FDA update! February’s regulatory news was characterized by updates in the men’s and women’s health space, in addition to a notable milestone in the development of an investigational agent for urothelial carcinoma. At the end of February, the field also saw 2 FDA submissions for belzutifan-based combinations in kidney cancer based on data presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.

Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.